Gabapentin Capsule
Product Images NDC 60760-939

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 60760-939). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (66c3584b 21d1 450a 8bfe Ba096129b91a 01)

A formula panel showing the calculation for creatinine clearance (CLCr) based on age, weight, and serum creatinine, including an adjustment factor of 0.85 for female patients.*

FDA Label Image

Figure1 (66c3584b 21d1 450a 8bfe Ba096129b91a 02)

Chemical structure of gabapentin, depicting a cyclohexane ring connected to an amino group (CH2NH2) and a carboxylic acid group (CH2CO2H).*

FDA Label Image

Image 1 (66c3584b 21d1 450a 8bfe Ba096129b91a 03)

A line graph showing mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, segmented into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores. Gabapentin treatment steadily decreases mean pain scores compared to placebo over time.*

FDA Label Image

Image 2 (66c3584b 21d1 450a 8bfe Ba096129b91a 04)

Line graph showing mean pain score over 7 weeks comparing placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day. The x-axis represents weeks from baseline to week 7, and the y-axis represents mean pain score from 0 to 10. Data depict a 3-week dose titration period followed by a 4-week fixed dose period. Gabapentin groups show a decrease in pain scores over the period, lower than placebo.*

FDA Label Image

Image 3 (66c3584b 21d1 450a 8bfe Ba096129b91a 05)

A bar graph titled 'Proportion of Responders (patients with a 50% reduction in pain score) at Endpoint: Concomitant PHN Studies.' It compares response rates between placebo (PBO) and Gabapentin (GBP) at different dosages (3600 mg, 1800 mg, 2400 mg) across two studies labeled Study 1 and Study 2.*

FDA Label Image

Image 4 (66c3584b 21d1 450a 8bfe Ba096129b91a 06)

A scatter plot chart showing the relationship between daily dose (mg) on the x-axis and percentage difference (%) on the y-axis with data points labeled for Study a, Study b, and Study c. The chart illustrates dose-dependent differences at various doses ranging from 600 mg to 1800 mg.*

FDA Label Image

60760-939 (Gabapentin 60760 939 60)

Gabapentin Capsules USP 100 mg label showing a quantity of 60 capsules. The label includes the NDC 60760-939-60, RX number 0000000000, and placeholders for lot number and expiration date. Manufactured by Strides Pharma Inc. in East Brunswick, NJ, and packaged by St. Mary's Pharmacy in Oro Valley, AZ. Storage instructions note controlled room temperature of 15°-30°C (59°-86°F).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.